EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Embryo‐fetal developmental toxicity study design for pharmaceuticals

L David Wise, Jochen Buschmann, Maureen H Feuston, J Edward Fisher, Kok Wah Hew, Alan M Hoberman, Steven A Lerman, Yojiro Ooshima, Donald G Stump

Birth Defects Research Part B: Developmental and Reproductive Toxicology · 2009-12 · 86 (6) · 418-428

DOI: 10.1002/bdrb.20214 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Birth Defects Research Part B: Developmental and Reproductive Toxicology, online erschienen am 18.12.2009. Verfasst von L David Wise und 8 weiteren Autor:innen. Beteiligte Einrichtung: Merck Research Laboratories, West Point, Pennsylvania 19486, USA. ld_wise@merck.com. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Drug Evaluation, Preclinical, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the International Conference on Harmonization (ICH) S5(R2) document (available at http://www.ich.org ). The studies that assess developmental hazard are generally conducted in rodents and rabbits. Based on the authors' collective experience, adequate designs (including range‐finding studies) and the presentation of data for these studies are described in detail. In addition, the suggested initiation and then total duration of these studies in relation to clinical studies that enroll women of childbearing potential are described. Optional parameters that may be included in the studies are discussed, as are study designs that combine assessments of fertility and developmental toxicity. New methods that may replace or enhance current procedures are outlined. The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies. Birth Defects Res (Part B) 86:418–428, 2009. © 2009 Wiley‐Liss, Inc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abnormalities, Drug-InducedDrug Evaluation, PreclinicalDrug-Related Side Effects and Adverse ReactionsAnimalsAnimals, Inbred StrainsEmbryonic DevelopmentFemaleFetal DevelopmentInternational AgenciesInternational CooperationMaleMaternal ExposureMiceRabbitsRatsResearch DesignToxicity Tests

Autor:innen und Institutionen

  • Merck Research Laboratories, West Point, Pennsylvania 19486, USA. ld_wise@merck.com

Zitieren

APA

Wise, L. D., Buschmann, J., Feuston, M. H., Fisher, J. E., Hew, K. W., Hoberman, A. M., Lerman, S. A., Ooshima, Y., & Stump, D. G. (2009). Embryo‐fetal developmental toxicity study design for pharmaceuticals. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 86(6), 418-428. https://doi.org/10.1002/bdrb.20214

Vancouver

Wise LD, Buschmann J, Feuston MH, Fisher JE, Hew KW, Hoberman AM, et al. Embryo‐fetal developmental toxicity study design for pharmaceuticals. Birth Defects Research Part B: Developmental and Reproductive Toxicology. 2009;86(6):418-428. doi:10.1002/bdrb.20214

BibTeX
@article{Wise2009,
  author = {Wise, L David and Buschmann, Jochen and Feuston, Maureen H and Fisher, J Edward and Hew, Kok Wah and Hoberman, Alan M and Lerman, Steven A and Ooshima, Yojiro and Stump, Donald G},
  title = {Embryo‐fetal developmental toxicity study design for pharmaceuticals},
  journal = {Birth Defects Research Part B: Developmental and Reproductive Toxicology},
  year = {2009},
  volume = {86},
  number = {6},
  pages = {418--428},
  doi = {10.1002/bdrb.20214}
}
Kostenlos starten →